期刊文献+

真实世界证据改善儿童药物临床试验障碍的对策研究 被引量:6

Real world evidence ameliorates barriers to drug clinical trials in children
原文传递
导出
摘要 本文旨在为加快我国儿童药物的研发,促进儿童药物临床试验的顺利开展。通过文献分析,发现我国儿童药物临床试验存在动力不足的问题,主要原因在于伦理要求高、招募工作难以开展、临床试验风险高、时间长、试验设计复杂和评价困难等,因此尝试利用真实世界证据来解决这些难题。真实世界证据的应用可以扭转儿童药物临床试验的困境,但在运用过程中存在挑战。随着真实世界证据的不断发展和完善,未来能为儿童药物临床试验环节的监管决策提供足够的依据,促进真实世界证据在儿童药物临床试验领域的应用。 The aim of the article is to promote the smooth development of clinical trials of pediatric drugs in China and to accelerate their research and development.Through literature analysis,it was found that the motivation of clinical trial of pediatric drug in China was insufficient,mainly due to high ethical requirements,difficulty in recruiting subjects,high risk,long clinical trial time,complicated trial design and difficult evaluation,etc.Thus we try to use real-world evidence to resolve these difficulties.The application of real-world evidence can reverse the dilemma of clinical trials of pediatric drug,but challenges in the application process still exist.With the continuous development and improvement of real-world evidence,it can provide sufficient basis for regulatory decisions in clinical trials of pediatric drugs in the future,and promote the application of real-world evidence in pediatric drug clinical trials.
作者 王璐 黄哲 WANG Lu;HUANG Zhe(College of Business Administration,2 Research Institute of Drug Regulatory Science,Shenyang Pharmaceutical University,Shenyang 110016,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2022年第19期1872-1875,共4页 Chinese Journal of New Drugs
基金 辽宁省自然科学基金资助项目(2020-MS-194) 2020年辽宁省高等学校创新人才支持计划项目(202002) 沈阳市2020年度科技人才项目(RC200498) 沈阳药科大学中青年教师事业发展支持计划资助项目(ZQN2018010) 沈阳药科大学药品监管科学研究院专项基金资助项目(2021jgkx005) 2020年度辽宁省科学事业公益研究基金资助项目(2020JH4/10100018) 辽宁省教育厅重点项目(2019WZD02)。
关键词 真实世界证据 儿童药物 药物临床试验 real world evidence children’s medicines clinical trials of drugs
  • 相关文献

参考文献11

二级参考文献125

  • 1柴家财,王亮,杜守业.正确认识知情同意书[J].中国病案,2005,6(3):22-23. 被引量:31
  • 2胡善联.上市后药物的经济学评价[J].中国循证医学杂志,2005,5(5):353-356. 被引量:19
  • 3赵西巨.知情同意:要素构成与过程优化[J].中国医学伦理学,2005,18(3):13-17. 被引量:21
  • 4汪秀琴,熊宁宁,刘沈林,李七一,蒋萌,刘芳,邹建东,高维敏,薛学坤.儿童与未成年人临床试验的伦理审查[J].中国新药杂志,2007,16(6):417-420. 被引量:20
  • 5I C. Regulation of drugs for children in Europe[ J]. BMJ ,2007,335 (7632) : 1221 - 1222.
  • 6European Medicines Agency. Questions and answers on the paediatric use marketing authorisation (PU- MA) [ EB/OL]. http://www, ema. europa, eu/ docs/en _ GB/document _ library/Other/2011/09/ WCS00112071. pdf,2013 - 10 - 01.
  • 7European Commission. Paediatric Investigation Plan[ EB/OL 1- http ://www. child - medicines - research - info. com/paediatrieresearch - consultancy/paediatric - investigation - plans. asp ,2013 - 10 - 01.
  • 8European union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population [ J ]. European Journal of Health Law ,2008,15 (2) :223 - 250.
  • 9Wendler D, Rackoff JE, Emanuel E J, C. G. The ethics of paying for childreng participation in re- search [ J ]. The Journal of Pediatrics, 2002,141 (2) :166 - 171.
  • 10R D. Lump sums for children taking part in re- search may distort parents " judgment [ J ] British Medical Journal,2002,325 (7368) :796.

共引文献100

同被引文献58

引证文献6

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部